Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors

被引:18
作者
Belal, Amany [1 ,2 ]
机构
[1] Taif Univ, Coll Pharm, Dept Pharmaceut Chem, At Taif 21974, Saudi Arabia
[2] Beni Suef Univ, Fac Pharm, Dept Med Chem, Bani Suwayf 62514, Egypt
关键词
Pyrrolizine; Pyrimidopyrrolizine; Anticancer; EGFR tyrosine kinases; TK inhibitors; GROWTH-FACTOR RECEPTOR; N-OXIDES; AGENTS; DERIVATIVES; ANALOGS; BINDING; KINASES; CANCER; DESIGN;
D O I
10.1016/j.bioorg.2015.02.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A new series of pyrrolizine derivatives 4-8c were synthesized, their structures were confirmed by spectral and elemental analyses. Cytotoxic activity of these compounds was evaluated against breast (MCF7), colon (HCT116) and liver (HEPG2) cancer cell lines using sulphorhodamine-B (SRB) assay method. All the tested compounds showed highly potent activity against MCF7 cell line with IC50 range equal 8-194 nM/ml and compound 8c was the best active one (IC50 = 8.6 nM/ml). 8b was the best active compound on both HCT116 and HEPG-2 cancer cell lines; its IC50 is 26.5 and 12.3 nM/ml respectively. Docking studies into ATP binding site of EGFR tyrosine kinase were performed to predict their scores and mode of binding to amino acids, moreover, inhibitory activity of these compounds against EGFR-TKs was evaluated; their inhibitory percent ranged from 40.4 to 97.6, compound 8c and 8b showed inhibitory activity at 97.6% and 88.4% respectively. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:124 / 129
页数:6
相关论文
共 26 条
[1]  
ANDERSON WK, 1980, ARZNEIMITTEL-FORSCH, V30-1, P765
[2]  
[Anonymous], 2013, [No title captured], Patent No. [20130197051, US 20130197051 A1]
[3]   A General Framework for Inhibitor Resistance in Protein Kinases [J].
Balzano, Deborah ;
Santaguida, Stefano ;
Musacchio, Andrea ;
Villa, Fabrizio .
CHEMISTRY & BIOLOGY, 2011, 18 (08) :966-975
[5]   Pyrrolizines: Promising scaffolds for anticancer drugs [J].
Belal, Amany ;
El-Gendy, Bahaa El-Dien M. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (01) :46-53
[6]   STUDIES ON THE PYRROLIZIDINE ANTITUMOR AGENT, CLAZAMYCIN - INTERCONVERSION OF CLAZAMYCIN-A AND CLAZAMYCIN-B [J].
BUECHTER, DD ;
THURSTON, DE .
JOURNAL OF NATURAL PRODUCTS, 1987, 50 (03) :360-367
[7]   The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations [J].
Cheng, Yuanhua ;
Cui, Wei ;
Chen, Quan ;
Tung, Chen-Ho ;
Ji, Mingjuan ;
Zhang, Fushi .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2011, 25 (02) :171-180
[8]  
ETIENNE A, 1969, B SOC CHIM FR, P3704
[9]   Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer [J].
Fernandes, Celia ;
Oliveira, Cristina ;
Gano, Lurdes ;
Bourkoula, Athanasia ;
Pirmettis, Ioannis ;
Santos, Isabel .
BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (12) :3974-3980
[10]   PREVALENCE OF ABERRANT EXPRESSION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN CANCERS [J].
GULLICK, WJ .
BRITISH MEDICAL BULLETIN, 1991, 47 (01) :87-98